Atai Beckley N.V. (ATAI) is a Buy on Mental Therapeutics Opportunities

Atai Beckley N.V. (NASDAQ:ATAI) is one of the best penny stocks to buy in 2026. On December 23, Jones Trading initiated coverage of Atai Beckley N.V. (NASDAQ:ATAI) with a Buy rating and a $16 price target. According to the research firm, the company boasts of differentiated opportunities owing to its pipeline of psychedelic and empathogenic drugs targeting considerable neuropsychiatric indications.

Jones Trading expects Atai Beckley to benefit from emerging trends favoring the development of drugs in different classes. For starters, the company is well-positioned to benefit from its lead assets, BPL-003 and VLS-01, for the treatment of resistant depression (TRD). Additionally, the research firm is buoyed by the TRD market, which is large enough and has sufficient unmet need to accommodate multiple treatments.

The positive stance comes on the heels of the company developing its pipeline backed by a strengthened balance sheet, following the raising of $300 million. It has also advanced multiple clinical programs into late-stage development. The company has also deepened its position in next-generation mental health therapeutics through its strategic partnership with Beckley Psytech.

“As we look ahead, AtaiBeckley is entering a pivotal phase and is well positioned to translate scientific leadership into long-term value for both patients and shareholders, as our recent addition to the NBI further validates,” said Srinivas Rao, Chief Executive Officer of AtaiBeckley.

Atai Beckley N.V. (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company that develops treatments for mental health disorders. The Company’s pipeline includes psychedelic and non-psychedelic compounds targeting depression, anxiety, and other unmet needs in psychiatry.

READ NEXT: Top 10 Materials Stocks to Buy According to Analysts and 10 Best Organic Food and Farming Stocks to Buy Now.

Disclosure: None. This article is originally published at Insider Monkey.